New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
05:55 EDTAON, AON, PRGO, PRGO, NWL, NWL, NOV, NOV, MRK, MRK, MAT, MAT, LYB, LYB, LM, LM, IR, IR, BEN, BEN, XOM, XOM, CVX, CVX, BEAM, BEAM, TSN, TSNCompanies reporting Before the Market Open on FridayFebruary 1
Notable companies reporting before the opening bell on Friday include Aon (AON), Beam (BEAM), Chevron (CVX), Exxon Mobil (XOM), Franklin Resources (BEN), Ingersoll-Rand (IR), Legg Mason (LM), LyondellBasell Industries (LYB), Mattel (MAT), Merck (MRK), National Oilwell Varco (NOV), Newell Rubbermaid (NWL), Perrigo (PRGO), and Tyson Foods (TSN).
News For AON;BEAM;CVX;XOM;BEN;IR;LM;LYB;MAT;MRK;NOV;NWL;PRGO;TSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 22, 2015
10:06 EDTPRGOAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:34 EDTIRIngersoll-Rand debuts UP6S fixed speed rotary screw compressor solution
Subscribe for More Information
07:14 EDTPRGOPerrigo agrees to acquire Yokebe
Subscribe for More Information
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:39 EDTCVX, XOMEuro, U.S. oil and gas groups to find tough competition in Iran, WSJ says
European and U.S. oil and gas firms drawn to Iran as sanctions lessen can expect not only opportunities, but also Iranian companies offering tough competition or joint ventures, the Wall Street Journal reports. Though no Iran-based companies have the clout of firms such as Exxon Mobil (XOM) or Schlumberger (SLB), companies that can take on engineering tasks are emerging and growing in Iran, the report says. If the Iran nuclear agreement comes into effect and sanctions are lifted against Iran sometime soon, those Iranian companies will be well positioned to compete for tens of billions of dollars worth of service contracts, the report adds. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:13 EDTXOMExxon Mobil upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
10:24 EDTMATOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTNWLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:45 EDTNWLNewell Rubbermaid initiated with a Buy at Sterne Agee CRT
Subscribe for More Information
13:20 EDTBENOptions with increasing put volume: CPN AKS HST BEN TTM
July 17, 2015
10:05 EDTNOVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Accretive Health (ACHI) downgraded to Market Perform from Outperform at Cowen... Allergan (AGN) downgraded to Outperform from Top Pick at RBC Capital... Best Buy (BBY) downgraded to Underperform from Buy at BofA/Merrill... Cablevision (CVC) downgraded to Hold from Buy at Jefferies... Credit Suisse (CS) downgraded to Hold from Buy at Deutsche Bank... Domino's Pizza (DPZ) downgraded to Sector Weight from Overweight at KeyBanc... First Quantum Minerals (FQVLF) downgraded to Neutral from Outperform at Credit Suisse... First Republic (FRC) downgraded to Market Perform from Outperform at FBR Capital... Fresenius SE (FSNUY) downgraded to Neutral from Buy at Goldman... Golden Minerals (AUMN) downgraded to Neutral from Buy at Roth Capital... JD Wetherspoon (JDWPY) downgraded to Reduce from Neutral at Nomura... NV5 Holdings (NVEE) downgraded to Neutral from Accumulate at Global Hunter... National Oilwell (NOV) downgraded to Sell from Neutral at UBS... Natural Gas Services (NGS) downgraded to Neutral from Buy at Global Hunter... Primoris (PRIM) downgraded to Neutral from Accumulate at Global Hunter... Receptos (RCPT) downgraded to Hold from Buy at Evercore ISI... SKF AB (SKFRY) downgraded to Hold from Buy at Deutsche Bank... STAG Industrial (STAG) downgraded to Sell from Neutral at UBS... SolarWinds (SWI) downgraded to Hold from Buy at Deutsche Bank... Syntel (SYNT) downgraded to Market Perform from Outperform at William Blair... TECO Energy (TE) downgraded to Neutral from Buy at UBS... Tangoe (TNGO) downgraded to Underweight from Equal Weight at Barclays... Tegna (TGNA) downgraded to Hold from Buy at Evercore ISI.
08:38 EDTPRGOLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
05:36 EDTNOVNational Oilwell downgraded to Sell from Neutral at UBS
Subscribe for More Information
July 16, 2015
17:20 EDTMATMattel continues to believe 2015 outlook achievable
Subscribe for More Information
17:08 EDTMATMattel remains on track for cost reductions
Comments from Q2 earnings conference call.
16:08 EDTMATMattel reports Q2 adjusted EPS 1c, consensus (4c)
Reports Q2 revenue $998.2M, consensus $995.36M.
15:17 EDTMATMattel July 25 straddle priced for 5.6% movement into Q2
15:02 EDTMATNotable companies reporting after market close
Subscribe for More Information
11:58 EDTMATMattel technical comments before earnings
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use